Pain, depression, and quality of life in adults with MOG?antibody–associated disease

Background and purpose Myelin oligodendrocyte glycoprotein-antibody–associated disease (MOGAD) is an inflammatory autoimmune condition of the central nervous system. However, data on pain depression have remained scarce. The aim this study was to assess features chronic as well their impact health-related quality life (hr-QoL) in MOGAD. Methods Patients with MOGAD were identified Neuromyelitis Optica Study Group registry. Data acquired by a questionnaire, including clinical, demographic, (PainDetect, Brief Pain Inventory–Short Form, McGill Questionnaire–Short Form), (Beck Depression Inventory-II), hr-QoL (Short Form-36 Health Survey) items. Results Twenty-two 43 patients suffered from MOGAD-related (11 nociceptive, eight definite neuropathic, three possible neuropathic) 18 depression. neuropathic had highest intensity most profound activities daily living (ADL) impairment. Fifteen reported spasticity-associated pain, four short-lasting painful tonic spasms. Later onset, physical impairment, associated pain. Physical QoL more affected sufferers (p < 0.001) than pain-free patients, being severely reduced = 0.016). severity, visual gait impairment independently predicted lower QoL. only factor reducing mental Twelve still suffering moderate (pain severity 4.6 ± 2.3) received medication. Only out 10 severe took antidepressants. Conclusions Being highly prevalent, strongly affect ADL Both conditions remain insufficiently controlled real-life clinical practice.